LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)

Company Profile

Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers. The firm encompasses that inhibitors of protein phosphatases have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company is focused on development activities of its LB-100 series of drugs. The LB-100 series have activity against a broad spectrum of common and rarer human cancers in cell culture systems. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Company Info

LIXTE BIOTECHNOLOGY HOLDINGS

No. 2, 248 Route 25A

East Setauket NEW YORK 11733

P: 13102032902

CEO: John S. Kovach

Employees: 3

Website: https://lixte.com/